Listing Results CheckMate Breast Cancer Login
About 19 results and 3 answers.
Checkmate Pharmaceuticals
12 hours ago At Checkmate Pharmaceuticals, we believe that every person living with cancer should have the best odds for better outcomes. Our goal is to enable more people with cancer to benefit from the promise of immunotherapies. Based on extensive experience in pharmaceutical and biologic discovery and our work with Toll-like receptor (TLR) therapies, we ...
Show more
See More
Study of Nivolumab Versus Placebo in Combination With
9 hours ago Sep 30, 2019 . Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) …
Show more
See More
CheckMate - Apps on Google Play
2 hours ago CheckMate protects your information so you can share your results with partners. We understand how uncomfortable traditional STD testing can be so we’ve created CheckMate to change the way people get tested, get treated and share results for a more comfortable dating world. Features: CheckMate Home 1. Select a test kit. 2.
Show more
See More
CheckMate 204: 3-year outcomes of treatment with
11 hours ago 2 Department Of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, 77030 - Houston/US 3 Neuro-oncology, Moffitt Cancer Center and Research Institute, 33612 - Tampa/US 4 Medical Oncology, Massachusetts General Hospital, 02215 - Boston/US
Show more
See More
Benefit of I-O/chemo combo over chemotherapy alone in
11 hours ago The addition of nivolumab to chemotherapy demonstrated improved survival benefit along with an acceptable safety profile, while maintaining tolerability and quality of life in patients with gastric cancer/gastric-oesophageal junction cancer and oesophageal adenocarcinoma (GC/GEJC/EAC), additional data from CheckMate 649 showed. Standard chemotherapy for advanced GC/GEJC/EAC …
Show more
See More
Neoadjuvant nivolumab plus chemotherapy improves surgical
10 hours ago The results from CheckMate 816 showed that patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab plus chemotherapy had improved pathologic complete response (pCR) rates and improved surgical outcomes. The randomised, phase 3 CheckMate 816 trial (NCT02998528) evaluates the efficacy and safety of neoadjuvant therapy with …
Show more
See More
CheckMate 649: Nivo + CT for GEC - Capsule Summary
9 hours ago Data from ASCO 2021 on the CheckMate 649 trial of first-line nivolumab + chemotherapy for gastroesophageal cancer, as reported by Clinical Care Options (CCO)
Show more
See More
CheckMate Breast Cancer - Home Facebook
11 hours ago CheckMate Breast Cancer. 49,011 likes · 4 talking about this. CheckMate Breast Cancer is an initiative by ColoursFM 101.6 to inform and guide women for self-examination and early detection of the...
Show more
See More
CheckMate 511 NIVO/IPI Dosing - Capsule Summary Slidesets
9 hours ago CheckMate 511 3-year follow-up comparing 2 NIVO/IPI dosing regimens for patients with advanced melanoma from ASCO 2021, as reported by Clinical Care Options (CCO)
Show more
See More
Nivolumab Plus Ipilimumab for Metastatic ... - Cancer Cell
9 hours ago CheckMate 650 is an ongoing open-label, multi-cohort trial evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Eligible enrolled patients were ≥18 years of age with histologically confirmed adenocarcinoma of the prostate and evidence of metastatic disease.
Show more
See More
Long-Term Neoadjuvant Study Tests ... - Breast Cancer
8 hours ago Investigators are evaluating the addition of nivolumab (Opdivo) to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor (ER)–positive/ HER2-negative breast cancer to determine whether the PD-1 immune checkpoint inhibitor can improve recurrence rates. CheckMate 7FL (NCT04109066) is a large, long-term phase 3 trial ...
Show more
See More
A Study of Nivolumab by Itself or Nivolumab Combined With
7 hours ago Aug 23, 2013 . To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC).
Show more
See More
Adjuvant Nivolumab Prolongs DFS in Patients with Resected
5 hours ago In CheckMate 577 study conducted among patients with resected oesophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab was associated with a significantly longer disease-free survival (DFS) than placebo. The safety profile of nivolumab was similar to that seen in other solid tumours.
Show more
See More
Trial of nivolumab plus ipilimumab for first-line HNSCC
2 hours ago A phase 3 trial of nivolumab plus ipilimumab vs. the EXTREME regimen as first-line treatment of advanced squamous cell carcinoma of the head and neck failed to meet its primary endpoints of OS ...
Show more
See More
Proffered Paper session - Head and neck cancer, excl. thyroid
9 hours ago
Show more
See More
CHEK2 Germline Variants in Cancer Predisposition
5 hours ago Compared with monoallelic carriers, biallelic carriers developed breast cancer more frequently (81% vs. 41%; p < 0.0001) and more likely before the age of 50 (61% vs. 24%; p < 0.0001), they developed secondary breast cancer with a higher frequency (23% vs. 8%; p = 0.01), and finally they had a higher risk of developing any primary cancer and ...
Show more
See More
First-Line Nivolumab Plus Ipilimumab May Offer Greater
1 hours ago The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months. Source: Getty Images Compared ...
Show more
See More
Combo Provides Lasting Benefit in Asymptomatic Patients
3 hours ago The 3-year intracranial progression-free survival rate was 54% in asymptomatic patients and 18.9% in symptomatic patients. Source: Getty Images …
Show more
See More
Oncology Data Advisor - Nivolumab Approved for Resected
7 hours ago CheckMate 577 enrolled 794 patients with completely resected esophageal or GEJ cancer who had been previously treated with concurrent chemoradiotherapy and who had residual pathologic disease. Patients were randomized in a 2:1 ratio to receive nivolumab 240 mg or placebo every two weeks for 16 weeks, followed by nivolumab 480 mg or placebo ...
Show more
See More
Frequently Asked Questions
How does Checkmate pharmaceuticals help people with cancer?
At Checkmate Pharmaceuticals, we believe that every person living with cancer should have the best odds for better outcomes. Our goal is to enable more people with cancer to benefit from the promise of immunotherapies.
Where is checkmate Pharmaceuticals in New York City?
Checkmate Pharmaceuticals is a team of scientists, physicians and life sciences entrepreneurs dedicated to discovering and developing new approaches to fighting cancer. Together, we’re striving to checkmate cancer. Contact Us. Checkmate Pharmaceuticals 245 Main Street, 2nd Floor
When was checkmate 577 published in the New England Journal of Medicine?
Ronan J. Kelly of the Baylor University Medical Center in Dallas, TX, US and colleagues published the CheckMate 577 findings on 1 April 2021 in The New England Journal of Medicine. The authors wrote in the study background that the incidence of oesophageal and gastroesophageal junction adenocarcinomas continues to increase in Western countries.